The Tettamanti Foundation (Monza) and the San Raffaele Telethon Institute in Milan have published a landmark study in the international journal Molecular Therapy: Methods and Clinical Development on a rare hereditary condition that affects infants from birth. Mucopolysaccharidosis Type I is caused by a deficiency that inhibits the body from manufacturing an enzyme required for the elimination of certain metabolic byproducts. As a result, hazardous material gradually accumulates in many organs, posing major risks to the brain, skeleton, and other critical systems. The study's originality resides in the timing of the intervention: delivering the gene therapy right after birth, before symptoms show, has the potential to greatly improve patients' quality of life. Experimental model analyses indicated greater levels of the missing enzyme, a reduction in hazardous chemicals accumulating in organs, improvements in skeletal alterations (which are often resistant to traditional therapies), and encouraging indicators in the brain. These are still preliminary findings, but they offer a tangible step toward more effective therapeutics for an illness for which existing treatments are limited and frequently only partially curative.